BAT Working On Possible Covid19 Vaccine Through US Bio-Tech Subsidiary

By Soko Directory Team / April 1, 2020 | 2:22 pm



UON COVID-19 coronavirus

BAT’s US biotech subsidiary, Kentucky BioProcessing (KBP), is developing a potential vaccine for COVID-19 and is now in pre-clinical testing.

If testing goes well, BAT is hopeful that, with the right partners and support from government agencies, between 1 and 3 million doses of the vaccine could be manufactured per week, beginning in June.

While KBP remains a commercial operation, the intention is that its work around the Covid-19 vaccine project will be carried out on a not for profit basis.

The vaccine in development uses BAT’s proprietary, fast-growing tobacco plant technology which has several advantages over conventional vaccine production technology:

It is potentially safer given that tobacco plants can’t host pathogens that cause human disease.

It is faster because the elements of the vaccine accumulate in tobacco plants much more quickly – 6 weeks in tobacco plants versus several months using conventional methods.

The vaccine formulation KBP is developing remains stable at room temperature, unlike conventional vaccines which often require refrigeration.

It has the potential to deliver an effective immune response in a single dose.

BAT’s US subsidiary, Reynolds American Inc, acquired KBP in 2014, with the aim of using some of its unique tobacco extraction technology to aid further development of its new category non-combustible products.

In 2014, KBP made headlines as one of the few companies with an effective treatment for Ebola, having manufactured ZMapp™ with California-based company Mapp Biopharmaceuticals in partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA).

KBP recently cloned a portion of COVID-19’s genetic sequence which led to the development of a potential antigen – a substance that induces an immune response in the body and in particular, the production of antibodies.

This antigen was then inserted into tobacco plants for reproduction and, once the plants were harvested, the antigen was then purified, and is now undergoing pre-clinical testing.

BAT is now exploring partnerships with government agencies to bring its vaccine to clinical studies as soon as possible. Through collaborations with government and third-party manufacturers, BAT believes that between 1 and 3 million doses per week could be manufactured.

 Dr. David O’Reilly, Director of Scientific Research, BAT said: “We are engaged with the US Food and Drug Administration and are seeking guidance on the next steps. We have also engaged with the UK’s Department for Health and Social Care, and BARDA in the US, to offer our support and access to our research with the aim of trying to expedite the development of a vaccine for Covid-19.

 “Vaccine development is challenging and complex work, but we believe we have made a significant break-through with our tobacco plant technology platform and stand ready to work with Governments and all stakeholders to help win the war against Covid-19. We fully align with the United Nations plea, for a whole-of-society approach to combat global problems.”

“KBP has been exploring alternative uses of the tobacco plant for some time. One such alternative use is the development of plant-based vaccines. We are committed to contributing to the global effort to halt the spread of Covid-19 using this technology.”





About Soko Directory Team

Soko Directory is a Financial and Markets digital portal that tracks brands, listed firms on the NSE, SMEs and trend setters in the markets eco-system.Find us on Facebook: facebook.com/SokoDirectory and on Twitter: twitter.com/SokoDirectory

View other posts by Soko Directory Team


More Articles From This Author







Trending Stories










Other Related Articles










SOKO DIRECTORY & FINANCIAL GUIDE



ARCHIVES

2020
  • January 2020 (272)
  • February 2020 (310)
  • March 2020 (390)
  • April 2020 (322)
  • May 2020 (336)
  • June 2020 (74)
  • 2019
  • January 2019 (253)
  • February 2019 (216)
  • March 2019 (285)
  • April 2019 (254)
  • May 2019 (272)
  • June 2019 (251)
  • July 2019 (338)
  • August 2019 (293)
  • September 2019 (306)
  • October 2019 (313)
  • November 2019 (362)
  • December 2019 (320)
  • 2018
  • January 2018 (291)
  • February 2018 (219)
  • March 2018 (278)
  • April 2018 (225)
  • May 2018 (238)
  • June 2018 (178)
  • July 2018 (256)
  • August 2018 (249)
  • September 2018 (256)
  • October 2018 (287)
  • November 2018 (284)
  • December 2018 (185)
  • 2017
  • January 2017 (183)
  • February 2017 (194)
  • March 2017 (207)
  • April 2017 (104)
  • May 2017 (169)
  • June 2017 (205)
  • July 2017 (190)
  • August 2017 (195)
  • September 2017 (186)
  • October 2017 (235)
  • November 2017 (253)
  • December 2017 (266)
  • 2016
  • January 2016 (165)
  • February 2016 (165)
  • March 2016 (190)
  • April 2016 (143)
  • May 2016 (245)
  • June 2016 (182)
  • July 2016 (271)
  • August 2016 (248)
  • September 2016 (234)
  • October 2016 (191)
  • November 2016 (243)
  • December 2016 (153)
  • 2015
  • January 2015 (1)
  • February 2015 (4)
  • March 2015 (166)
  • April 2015 (108)
  • May 2015 (116)
  • June 2015 (120)
  • July 2015 (148)
  • August 2015 (157)
  • September 2015 (188)
  • October 2015 (169)
  • November 2015 (173)
  • December 2015 (207)
  • 2014
  • March 2014 (2)
  • 2013
  • March 2013 (10)
  • June 2013 (1)
  • 2012
  • March 2012 (7)
  • April 2012 (15)
  • May 2012 (1)
  • July 2012 (1)
  • August 2012 (4)
  • October 2012 (2)
  • November 2012 (2)
  • December 2012 (1)
  • 2011
    2010
    2009
    2008
    2007
    2006
    2005
    2004
    2003
    2002
    2001
    2000
    1999
    1998
    1997
    1996
    1995
    1994
    1993
    1992
    1991
    1990
    1989
    1988
    1987
    1986
    1985
    1984
    1983
    1982
    1981
    1980
    1979
    1978
    1977
    1976
    1975
    1974
    1973
    1972
    1971
    1970
    1969
    1968
    1967
    1966
    1965
    1964
    1963
    1962
    1961
    1960
    1959
    1958
    1957
    1956
    1955
    1954
    1953
    1952
    1951
    1950